Purpose . The aim of this work was to develop specific radiopharmaceutical and to evaluate its efficacy in human to detect and locate the tubercular lesion. Materials and Methods . 99mTc -Ethambutol (EMB) was produced by direct labeling method. In vitro and in vivo biological studies and animal experiments were done. Phase I Clinical trial was performed. As per plan, 2 normal human subjects for biodistribution studies and fourteen patients (8 males and 6 females; age range of 25–50, with one patient aged 12 years as an exception) were chosen for clinical trial. Whole body scan and spots were acquired at 1 hour and 4 hour. Angiography, blood pool, and 24-hours spot images of the infected areas were also acquired. Result . Radiolabeling yielded >85% of labeled complex. In vitro and in vivo biological studies and animal experiments indicated 99mTc -EMB as a specific tuberculosis imaging agent. The biodistribution study in normal human subjects suggested stability of 99mTc -EMB, with main excretory pathways being renal and hepatobiliary, which appeared to be similar to the known behavior of unlabeled EMB. No adverse reactions were observed. 99mTc -EMB got localized in pulmonary and bone tubercular lesions. Scintigrams of 99mTc -EMB and 99mTc -Ciprofloxacin were compared at different time intervals. Conclusion . The present study states that developed 99mTc -EMB has high potential to qualify as a specific tuberculosis imaging radiopharmaceutical and is safe for human use.
Singh, N., & Bhatnagar, A. (2010). Clinical Evaluation of Efficacy of 99m TC -Ethambutol in Tubercular Lesion Imaging . Tuberculosis Research and Treatment, 2010, 1–9. https://doi.org/10.1155/2010/618051